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1. Introduction
Abnormalities in the thyroid anatomy or physiology often arise when the clinician suspect
hyperthyroidism or hypothyroidism detecting on physical examination a goiter or a thyroid
nodule and confirms the suspicion by serum measurements of thyroxine (T4), or thyroid
stimulating hormone (TSH).
Hyperthyroidism is the result of several diseases that may be located in the thyroid gland
(primary), as well as in other locations (secondary), or be the product of an overeating of high-
iodinated foods or being an undesirable effect of some drugs (amiodarone, antitussives). They
will have different expressions in the clinical, laboratory and diagnostic imaging.
Primary hyperthyroidism is the most common condition where diseases like Graves Basedow
disease, toxic multinodular goiter and toxic adenoma are the most common pathologies.
Although rare, also the hyperthyroidism associated with thyroid carcinoma [1], extracervical
ectopic thyroid tissue [2], mutation with activation of the TSH receptor [3], activating muta‐
tions of the stimulatory G protein in the McCune-Albright syndrome [4], Struma Ovarii [5]
and medications such as the excess of iodine intake (Jod-Basedow phenomenon).
The secondary hyperthyroidism is characterized by an increased thyroid hormone caused by
extrathyroid pathologies like the TSH high secreting pituitary adenoma [7], thyroid hormone
resistance syndrome [8], human chorionic gonadotropin secreting tumor [9].
Within the thyrotoxicosis without hyperthyroidism will be the acute, subacute and silent
thyroiditis and other causes such as medication with amiodarone, radiation, adenoma
infarction or excessive thyroid hormone intake (factitious hyperthyroidism). These diseases
will present a clinical picture similar to hyperthyroidism.
All these pathology will need to be studied using various imaging techniques (Figure 1).
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Figure 1. Medical imaging devices used in Radiology and Nuclear Medicine Departments.
Imaging studies will be in the first line for thyroid exploration techniques. There will be others
that will serve to confirm or distinguish between thyroid pathologies as well as to locate
pathology in extracorporeal way when it is secondary.
2. Introduction to imaging studies
Ultrasonography is a technique of first choice, based on the study of the thyroid gland by the
emission and reception of ultrasound signal that according to its characteristic of reflection of
sound wave in the different tissues studied will display them in different graduations of gray
color on a scale that will go from white to black. Main advantages are their cost, non-invasive
and that they not emit ionizing radiation. Within the disadvantages will be the need for
experienced staff.
Then we will have a second imaging technique that will be of great importance in the study
of hyperthyroidism, the scintigraphy, a non-invasive technique that through the use of
radioactive material will be able to assess not only anatomy and glandular function, but
exploring the whole body searching for extraglandular pathology. Of additional contribution
will be the Radioactive Iodine Uptake (RAIU), is a test that evaluate the thyroid function,, it
measures how much radioactive iodine is taken up by the thyroid gland in a certain time
period, normally obtaining values in a few hours (4-6), 24 hours, and 48 hours.
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And two imaging methods of high resolution, computed tomography (CT) and magnetic
resonance imaging (MRI) techniques are used to assess cervical gland pathologies as well as
extracervical level giving a greater resolution than other imaging studies. It is useful in the
surgical planning and for their subsequent evaluation and monitoring. MRI will allow
improved visualization of soft tissues and the identification of pathologies at thoracic as in
abdominopelvic level.
When an intraglandular lesion is identified in thyroid, ultrasound technique will be useful for
the intralesional correct approach and extraction of material by the Fine Needle Aspiration
Biopsy (FNAB) for the cytopathology evaluation (Figure 2).
Figure 2. Fine needle aspiration biopsy guided by ultrasonography.
FNAB is the cornerstone in the solitary thyroid node assessment detected in the clinical exam
as well as the evaluation of the dominant node in multinodular goiter disease.
In places where a nodule or a lymph node is difficult to be identified by fisical exam, or if there
are multiple nodules, an echo-guided biopsy provides high precision for the nodule/ganglion
sampling.
As we mentioned above the procedure requires skilled and experienced hands as well as an
experienced cytopathologist. Even more, in experienced hands, 10% approximately of the
biopsies are non diagnostics.
Thyroid nodules are discovered by palpation in a 3-7 percent of cases and by ultrasound in a
20-76% in the general population [10].
3. Ultrasonography
The ultrasound images tend to be reserved for those cases in which there are doubts about
whether it is a nodule or palpable nodule is inside the thyroid. They are also used to distinguish
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between a suspicious nodule and a prominent lobe or thyroid hemiagenesis, to distinguish
between a solitary nodule and a multinodular goiter, for the evaluation of a thyroid mass when
cytology is not diagnostic.
Thyroid nodules are common. The most palpable nodules are benign (solid, cystic, mixed)
being the minor, less than 10%, malignant [11]; however, the risk of malignancy in nodule rises
in children, adolescents, and adults. The risk is substantially increased if the patient has been
previously irradiated by head and neck pathology [12].
Multiple publications have documented that certain sonographic features by B-mode ultra‐
sound and Doppler color, Figure 3, (hypoechogenicity, irregular margin, microcalcifications,
intralesional vascular signals) are suggestive of malignancy [13-17].
Figure 3. Colour Doppler of a thyroid nodule. In color is displayed the vascular distribution inside the nodule, showing
periferic and central vascularization. The image shows multiple microcalcifications too, being in relation to papillary
carcinoma. (Image courtesy by Dr. Alejandro Blando)
Ultrasound clearly defines the thyroid gland, it is more sensitive than scintigraphy in the
detection of thyroid nodules and determines their intra/extra glandular location. Ultrasound
is done when a clinician suspect the presence of a thyroid nodule or for the confirmation of
the location inside or outside the gland.
Although radiation dose in scintigraphic studies and RAIU are extremely low and that there
is no known health risk up to date, the ultrasonography avoid ionizing radiation and always
it is used as initial imaging technique for the gland evaluation in children. Also, the ultraso‐
nography is the initial imaging method for pregnancy assessment. In the presence of a nodule,
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the ultrasonography will be helpful in determinate his composition (cystic, solid, miced). The
ultrasound technique has an important limitation, being unable to differentiate between
malignant and benigne nodule, only giving an estimation.
Ultrasonography also can be used for the degree of the nodule growth in patients under
suppresing therapy. Their limitations are the necesity of experienced operator, high interop‐
erator variability in the nodule identification and the uncertain signification of the thyroid
micronodule in the moment of the detection in the adult population. The ultrasonography is
so sensitive and the nodules so prevalent that may be difficult to be interpreted in some
situations.
4. Doppler
Also the Doppler Ultrasonography is useful for the thyroid gland evaluation. It meassures the
vascular flow in the inferior thyroid artery, being 6 ml/min in norml gland and increased more
than 5-folds in hyperthyroidism. Doppler is very useful in Graves Disease for the global flow
increase assessment (Figure 4), also the therapeutic response control showing a flow constant
reduction and the posterior increase in case of recurrence.
Figure 4. Color Doppler Ultrasound of the Thyroid Gland in longitudinal view (image A) as in transversal view (image
B). High and diffuse hypervascular thyroid related to Graves Disease ("Thyroid Inferno Sign"). (Image courtesy by Dr.
Alejandro Blando).
In the last years also it has also been evaluated the Doppler utility in the nodule feature
determination between malignancy and benign as weel as inflamatory or malignant lymph
nodes [18].
5. Elastography
Even more, recent studies shows that are ultrasopnography techniques that reduce the false
negative probability using the Elastography Ultrasonographyic method, first described in
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thyroid lesions in 2005 by Lyshchik et al. [19] This method consist in the evaluation in real time
(RTE) of a region of interest during the aplication of external force with the probe of the
ultrasonography, the software meassure the tissue displacement wich is visualized in color
scale depending on the nodular/extranodular consistency. It has been reported as a great tool
that could optimize the thyroid nodule management because of his high sensitivity and
specificity in the prediction of thyroid carcinoma (Figure 5). [20,21]
Figure 5. Dual Modality US Imaging. There is a small hypoecoic solid nodule related to papillary carcinoma (image at
the left). Elastography method (image at the right) showing a nodular stiffness, hence the lack of nodular elasticity
represented as red colour between arrows. (Image courtesy by Dr. Alejandro Blando)
6. Thyroid scintigraphy and radioactive iodine uptake
Thyroid assessment by radionuclides can contribute to the management of the patient under
thyroid disease suspicious.
Thyroid scintigraphy helps to determinate the gland location, morfology and functional
features (Figure 6).
Unlike ultrasonography, the scintigraphy assess the thyroid nodule and gland physiology.
Hot nodules (Figure 7) acumulates I-123 or Tc-99m in a major degree than normal thyroid,
they are very uncommon to express malignancy and FNAB or surgery can be avoided.
Warm nodules acumulates radiotracers in the same intensity as normal thyroid tissue. They
are low probably to be malignant, but doctors would try FNAB depending on the size,
consistency and clinical presentation.
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Figure 6. Thyroid Scintigraphy with Tc-99m-Pertecnetate. Anterior, Left Oblique and Right Oblique projections (top
left, top right and botom right respectivelly) magnified with pin-hole collimator. Showing a normal thyroid gland with
a normal radiotracer distribution.
Figure 7. Thyroid Scintigraphy with Tc-99m-Pertecnetate in anterior projection. High focal uptake in right lobe related
to Toxic Nodular Adenoma. (Image courtesy by Dr. Charles Bouirsot)
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Cold nodules (Figure 8) lacks of radioisotope acumulation, they do not trap Tc-99m nor
organify I-123 either. They have a 10-20 % of probability of malignancy [22], for this reason,
the thyroid scintigraphy can be useful when a FNAB result is uncertain [23].
Figure 8. Thyroid Scintigraphy with Tc-99m-Pertecnetate in anterior projection. The image display a cold nodule (ar‐
row) in the right lobe. (Image courtesy by Dr. Charles Bouirsot)
The presence of toxic multinodular goiter diminish the malignancy risk. The typical multi‐
nodular scintigraphic image shows areas of high and low uptake of radiotracer and always
the two thyroid lobes affected (Figure 9). There are last articles that inform that multinodular
goiter and solitary nodules have the same risk of malignancy.
Nevertheless, the presence of a dominant cold nodule it will be recomended a FNAB (Figure
10).
Radioactive Iodine Uptake complements the thyroid scan, and can meassure the percentage
of glandular iodine uptake in order to find utility to the I-131 therapy (Figure 11). There are
pathologies in which uptake will be negligible and not I-131 therapy will be needed such as
subacute Thyroiditis, struma ovarii, or factitious hyperthyroidism.
The functional and structural information given by the Scintigraphy thyroid and thyroid
uptake combined with physical exam and hormonal serology always allows a correct diagnosis
and a logical therapeutic approach or next diagnostic procedures.
It is important to distinguish between hyperthyroidism associated with an increased iodine
uptake (Graves, BMN, toxic adenoma disease) and a decreased uptake (Thyroiditis, factitious
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hyperthyroidism, struma ovarii, functioning metastasis of thyroid carcinoma, extracervical
ectopic thyroid tissue), because the treatment for these two categories of hyperthyroidism is
going to be different.
The diagnosis of Graves disease can be based on clinical data and laboratory. A thyroid
scintigraphy and a thyroid uptake curve can be usefull to confirm the Graves disease when it
is a hyperthyroidism without signs of proptosis, pretibial myxedema and exophthalmos.
Thyroid scan shows a homogeneous uptake of radiotracer in both lobes. Sometimes the Graves
disease can be confused with toxic Multinodular goiter, but both can be easily recognized by
a thyroid scintigraphy. This differentiation is important because the therapeutic dose is much
higher for toxic Nodular goiter.
Occasionally, a silent or subacute thyroiditis can be confused with Graves disease because in
both situations the patient is hyperthyroid with abnormal analytic function. The patient with
thyroiditis may have fever, pain and local inflammation, but it could be confused with an
infection or inflammation of upper air tract. It could also happen that at the time of the elevated
thyroid hormones in blood the clinic of thyroiditis had already disappeared.
Figure 9. Thyroid Scitigraphy with Tc-99m-Pertecnetate, anterior projection images with different collimators (paralel
hole and pin-hole, top and bottom respectivelly). The images displayed show a great hyperactivity with heterogene‐
ous distribution in an enlarged thyroid gland (goiter) related to multinodular goiter.
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Figure 10. Thyroid Scintigraphy with Tc-99m-Pertecnetate. Anterior, Left Oblique and Right Oblique projections (top
left, top right and botom right respectivelly) magnified with pin-hole collimator. Showing a right enlarged thyroid
lobe (patient with hemithyroidectomy) with heterogenous distribution of the radiotracer. There is a hot nodule in the
upper pole and a cold area at the right of the midlower part of the lobe.
Figure 11. Radioactive Iodine Uptake Curve Plot. The image shows different uptake intensity (in percentage) depend‐
ing on the thyroid disease represented in time (hours).
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Because of glandular inflammation in acute or subacute Thyroiditis, this is not able to trap
Tc-99m or organify I-123, consequently, the capture of 24 hours will be close to 0% (Figure 12).
Figure 12. Thyroid Scintigraphy with Tc-99m-Pertecnetate in anterior projection with two different collimators (pin-
hole and paralel hole, left and right respectivelly). The image displayed show no uptake of radiotracer by the thyroid
gland.
The scintigraphy can be used to distinguish between the thyroiditis and Graves disease.
Another problem that can arise is that of a patient with hyperthyroidism in which we do not
know if the pathology is toxic adenoma or toxic multinodular goiter. Thyroid scintigraphy is
suitable technique for their differentiation. The importance of the difference between toxic
adenoma, multinodular goiter and Graves disease is that the first two needs higher therapeutic
dose.
Another situation is that the factitious hyperthyroidism where the scintigraphy will help
showing absence of glandular uptake and a radioactive iodine uptake value of 24 hours close
to 0%. The difference between thyroiditis and factitious hyperthyroidism will be through
laboratory, where the values of TG and Ac anti thyroid (AAT) will be the key.
Extremely rare conditions where a hyperthyroidism due to struma ovarii will supress the
thyroid  gland  activity  uptake.  24-Hour  uptake  will  be  close  to  0%.  If  this  condition  is
suspected, the solution will be a whole body Tc-99m scintigraphy or MRI imaging of the
pelvis. A case of struma ovarii is displayed in Figure 13.
There are also rare situations like functioning thyroid carcinoma metastases where they are
going to be seen enhanced hot spots dispersed in multiple parts of the body (Figure 14).
When a mass in neck or retrosternal area is detected and the suspicion could be a goiter,
Thyroid Scintigraphy will be of great use to confirm this suspicion. With the help of a cutaneous
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Figure 13. Thyroid Scintigraphy with I-131 in a patient under control for his thyroidectomy. There are displayed parti‐
ally wholebody scan and craneocervical and pelvic statics views in anterior projection. There is a fical uptake at cervical
level and a high activity mass lesion at the left hemipelvic region. This images is related to Struma Ovarii.
Figure 14. Thyroid Scintigraphy with I-131. Wholebody scanning in anterior and posterior views (at left) and cervico‐
mediastinal statics in anterior and posterior views (at right, top and bottom respectively).
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radioactive labelling at the level of the suprasternal notch location cervicomediastinal thyroid
or thyroid nodule in study can be defined with great precision.
A retrosternal goiter may be the manifestation of a multinodular goiter, which characteristi‐
cally will presents with decreased radiotracer uptake of the area. There has been publicated a
case of hyperthyroidism for multinodular ectopic goiter (Figure 15) where can be observed the
great utility that will have the anatomical as well as functional images [2].
Figure 15. Thyroid Scintigrahpy with I-131 radiotracer, Chest Radiograph, Axial contrast enhanced CT scan at media‐
stinum level and a the ectopic goiter extracted by surgery (Top left, top right, bottom left, bottom right, respectivelly).
Thyroid scintigraphy can also differentiate between benign adenomatous nodule or a hot
nodule. The scintigraphy is made after intravenous administration of thyroid hormone and
can differentiate between a hot nodule if this decrease its level of uptake or will still be hot
when we are in the presence of a autonomous node. It will be useful to measure the therapeutic
approach, where is going to be useful to use thyroid hormone in order to decrease the size of
the hot nodule not being useful to adenomatous autonomous nodules.
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Scintigraphic characteristics between I-123/I-131 and Tc-99m
I-123 / I-131 Tc-99m
∙ Half life: 13,22 Hs / 8 days
∙ Energy: 159 keV / 354 keV
∙ Administration path: oral
∙ Trasported actively to the intracelular space (Trapped)
∙ Bounded to thyrosine (Organified)
∙ The scintigraphy will show tissue distribution of both
functions (Trapped and Organified)
∙ 3-4 hs pos oral administration imaging
∙ Thyroid nodule evaluation
∙ Nodular function assessment
∙ To determine retrosternal mass
∙ To confirm the presence of Graves Disease
∙ To confirm the presence of multi nodular goiter
∙ To confirm the presence of toxic adenoma
∙ It is useful in Radioactive Iodine Uptake study and to
determine the I-131 dose for radiotherapy.
∙ Half life: 6,02 Hs
∙ Energy: 140 keV
∙ Administration path: intravenous
∙ Transported actively to the intracelular space (Trapped)
∙ NOT bounded to thyrosine (NOT organified)
∙ The scintigraphy will show distribution of the function of
Trap but no of organification.
∙ 10-30 minutes pos intravenous administration
∙ Thyroid nodule evaluation
∙ Nodular function assessment
∙ To determine retrosternal mass
∙ To confirm the presence of multi nodular goiter
∙ To confirm the presence of toxic adenoma
∙ The Thyroid uptake is not standardized like I-123 y Tc-
The measure of thyroid uptake has NO standard like I-123
y I-131, but can be evaluated in order to see the capacity of
the glandular trap.
7. Positron emission tomography
PET/CT study is a nuclear medicine imaging based on the gamma acquisition coming from
the aniquilation of the posittron emited by a radiotracer administered intravenously, that in
their majority of nuclear medicine centers is going to be F-18-FDG (fluorodeoxyglucose), useful
for the measurement of the glucose metabolism in the wholebody, being higher in those very
active and normal tissue (heart, brain, brown adipose tissue, Waldeyer ring), pathologic tissue
(adenomas, multinodular goiter, Graves disease, autoinmune disease, cancer) and the
radiotracer's collecting and excreting system (kidney, ureter, urinary bladder).
Primary hyperthyroidism will present a pathological increase in the activity of the thyroid
gland, which can be presented as a homogeneous hyperactivity as is the typical case of Graves
disease or can be a focal hyperactivity like toxic adenoma, which must be studied by FNAB
since the focal hyperactivity may also been caused by malignant processes such as papillary
or follicular carcinomas.
A recent publication relates the hyperthyroidism with an increase in the glucose metabolism
by the brown adipose tissue. That means a problem in the assessment in the cervical soft tissue
surrounding the thyroid gland because sometimes it is difficult to determine if the increased
focal activity comes from a lymph node, metastasis or brown adipose tissue [24].
The PET study also is useful for assessing patients with hyperthyroidism and its mental
behavior change. An article has been published in which there is a relationship between
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hyperthyroidism and alteration in brain glucose metabolism, showing a decrease in glucose
activity at the level of the limbic system (uncus and inferior temporal gyrus), metabolic
activation in the lower area of the parietal lobe and posterior cingulated level which was related
to depression and anxiety, this last symptom was also associated with the increased metabolic
activity at the level of the bilateral sensory associative cortex [25]
Multiple retrospective studies have reported that incidentalomas in thyroid gland with
increased focal uptake of F-18 FDG has been found in 1.2 to 4.3% of healthy patients under
study by PET/CT [26-29].
It was also suggested that a diffuse increase of the uptake into the thyroid gland was more in
relation with benign lesion such as chronic thyroiditis or Graves disease [30].
We display in Figure 16 a normal thyroid gland with a normal F-18 FDG activity.
Figure 16. PET/CT scan at the thyroid gland level. Axial CT scan, emission image at thyroid level, axial PET/CT hybrid
image and MIP emission image from mid-brain to bladder. The image displayed show an homogeneous activity in
both thyroid lobes related to normal gland activity.
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Although focal lesions with a high SUV (> 10) had a high probability of malignancy, the thyroid
lesions with SUV < 10 have not demonstrated a high probability of benign lesion.
Inside those non-FDG radiotracers, the I-124 used for volumetric meassure for dosimetric
planning in the treatment of hyperthyroidism with I-131, being their results better than those
obtained by ultrasonography or conventional scintigraphy [31-33]. Although I-124 is not
generally available and its use is limited to specialized centres.
Either, it has been done multiple studies with the radiotracer Ga-68 DOTATOC in an attempt
to find differences between benign and malignant thyroid diseases, but no good conclusion
were obtained. An increased DOTATOC uptake (target to background ratio >3.4) was found
in hot nodules, disseminated thyroid autonomy, and in most cases (5 of 8) of active Hashimo‐
to's disease. In Ga-68 DOTATOC PET, normal thyroid glands show a clearly detectable
radiotracer uptake with a large variability and significantly higher target to background ratios
in male patients. All patients with thyroid autonomy and most patients with active Hashimo‐
to's disease have an increased thyroid DOTATOC uptake [34].
8. Computed tomography and magnetic resonance imaging
Both studies are useful for the anatomic description in high resolution of the thyroid gland,
their nodes compositions, the adjacent structures characteristics when a thyroid goiter is
present (trachea and esophagous principally), ophtalmopaties associated to Graves Disease,
pituitary gland in secondary hyperparathyroidism, mediastinal structures in ectopic goiters
and pelvic alteration when a struma ovarii exist.
They will be useful in the gland meassurement for the surgery planning or metabolic therapy
with I-131.
In pos-therapy control period, both imaging studies are going to be useful for the follow-up
of the cervical and extracervical region.
One of the most undesirable effects that might occur in a thyroid enhanced contrast CT is the
induction of a thyrotoxicosis or thyroid storm [35-39].
9. Characteristic of imaging reports
9.1. Ultrasonography report
• Classification of a palpated nodule. eg solid, cystic, mixed
• Evaluate adjacent structures
• Determining the location of a palpable lump (within or outside of the thyroid)
• Identifying a cause for Hyperthyroidism
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• Post surgical complications eg abscess, oedema
• Multi Nodular Goiter: Follow up nodules
• Guidance of injection, aspiration or biopsy
• Relationship of normal anatomy and pathology to each other
9.2. Scintigraphic report
• Configuration of the thyroid gland (homogeneity, nodules, size, location)
• Nodules activity (hot-warm-cold) respect to normal thyroid parenchima
• Extracervical pathologic activities
• Wholebody physiologic activities
• Thyroid Radioiodide Uptake Curve (RAIU)
9.3. Positron emission tomography report
• Metabolic feature of the thyroid gland (homogeneity, size, location)
• Nodular metabolic activity respect the normal thyroid parenchima
• Metabolic activity of Thyroid Goiter
• Semicuantification by SUV (Standard Uptake Value)
• Metabolic scanning of the whole body
• Metabolic activity of the pituitary gland, mediastinum and genitals (secondary hyperthyr‐
oidism)
9.4. Computed tomography report
• Configuration of thyroid gland (homogeneity, nodules, size, location)
• Nódules density (solid, cystic, mixed, calcium inside, abscess)
• Cervical and mediastinal lymphadenopathies
• Extracervical metastatic lesions (cranial, thorax, abdomen, pelvis, limbs)
9.5. Magnetic resonance imaging report
• Configuration of thyroid gland (homogeneity, nodules, size, location)
• Nódules density (solid, cystic, mixed, abscess)
• Cervical and mediastinal lymphadenopathies
• Extracervical metastatic lesions (cranial, thorax, abdomen, pelvis, limbs)
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10. Metabolic radiotherapy
This therapy has a high success rate and carries a minimum risk. More than 80% of patients
are successfully treated with a single dose. The disadvantages are minimal between them:
• Hypothyroidism (0-45 %)
• cervical compressive symptoms (2-4 days post administration of I-131)
• acute inflammation
• post-radiation thyroiditis (1-5%) (5-10 days post administration of I-131)
• exacerbation of thyrotoxicosis (7-10 days post administration of I-131)
• development of Graves (< 1%) disease
• acute sialitis
If there is no suspicion of malignancy, metabolic radiotherapy is indicated when the goiter
causes local symptoms, such as dyspnoea or dysphagia. It is the therapy of choice, particularly
in elderly patients, with diseases that increase the risk of surgical results or have a recurrence
in post-surgery period (they have 10 times more likely to suffer damage to the laryngeal nerve).
The radiation dose to the thyroid following an administration of I-131 depends on:
• administered dose
• glandular size
• homogeneity in glandular distribution
• percentage of uptake at 24 hours
• Time of the I-131 inside the gland.
Patients with multi nodular goiter or toxic adenoma need one radioactive dose greater than
grave's disease to achieve an euthyroid state.
10.1. Meassuring procedure
The pretherapy dosimetry should include the following tasks [40]:
• Target mass delineation by sonography or other suitable procedure.
• Quantification of the tracer activity with a dose calibrator.
• Measurement of the tracer activity with the test device, probe or gamma camera, with the
activity located in the phantom or in free air with the relevant count rate correction.
• Verification that the observed count rate per activity matches the expected sensitivity value
of the device.
• Administration of the tracer activity with accurate documentation
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• If liquid 131I-NaI is administered, measurement of the residual activity and determination
of the activity administered and the corresponding count rate.
• In-vivo measurements of the 131I uptake in the target tissue at the times stated in section
Time lines.
• Calculation of the radioiodine activity needed for therapy according to section Data
evaluation.
10.2. Potential sources of error
The evaluation of the therapeutic activity necessary to administer a specified target dose might
be erroneous due to [40]:
• Errors in target volume determination
• Inappropriate attenuation correction (no or inadequate phantom)
• Contamination of the phantom
• Incorrect distance between the detector and the patient or phantom
• Deviation of the individual target tissue depth from the calibration depth
• Inappropriate centring of the probe over the phantom or the target tissue (target tissue
partially outside the probe’s FoV)
• Instability of the electronics of the measuring device, especially if quality control is inade‐
quate
• Variation in background count rate (e.g. from radiation emitted by other patients) for the
different uptake measurements
• Reduced or delayed absorption due to recent food intake
• Recent administration of another radionuclide
• Unfavourable choice of timing of the uptake measurements
11. Nanoparticles and future vision
According to Ramsden [41], increased vascularity in the thyroid can occur in hyperplastic
goiter, Graves' disease and cancer, and may be associated with a vascular hum because of
increased blood flow.
Interestingly, in experimental induction of goiter by low Iodine and thiouracil in rats, Wollman
et al. [42] showed that the capillaries within the thyroid clearly enlarged within 3 days of
treatment, and by 20 days, they surrounded the follicles with a continuous endothelial sheet.
There was both fusion of capillaries and mitosis of endothelial cells.
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Data suggest that, in human thyroid tumors, angiogenesis factors seem involved in neoplastic
growth and aggressiveness.
The thyroid is an excellent model for the integrated control of angiogenesis, because of the
vascularity of the thyroid gland, and its capacity to increase its blood flow in disease [43].
Biomolecular nanotechnology defined as “the threedimensional positional control of molec‐
ular structure to create materials and devices to molecular precision" recently has grown to
the multifaceted industry providing new approaches to the old problems [44].
Nanodevices can receive the natural chemical messages transmitted from and between cells
simply by eavesdropping on the natural molecular message traffic. Of course, mechanical (e.g.,
cytoskeletal) and electrical (e.g., ionic) cellular emanations may also be detectable by nanode‐
vices [44].
Nanoparticles have emerged as agents for diagnosis and treatment with the distinction of being
manipulated in their surface structure, thereby allowing a longer intravascular circulation
period, physical and chemical manipulation of nergy, and being directed specifically to the
target, achieving a target cell-specific uptake, allowing increased detection sensitivity through
pathological signal amplification [45].
The application of nanoparticle-labelbased all-in-one dry-reagent immunoassay for thyroid
stimulating hormone was reported by Huntinen et al. [46]. The magnetic properties of
magnetic nanoparticles (MNPs) allow them to be imaged via magnetic resonance imaging
(MRI) and targeted to a particular region by an externally applied MF (magnetic field). Once
loaded with drug, MNPs can be targeted to a region of interest through an externally applied
MF, and the drug released over a period of weeks. This helps to achieve optimal dosing by
reducing the systemic toxicity of the drug, and decreases the likelihood of drug resistance that
would result from insufficient drug present. Through MRI imaging, the biodistribution of
MNPs and indirectly the drug concentration may be determined [47].
Mousa et al. [48] described methods of treating subjects having conditions related to angio‐
genesis including administering an effective amount of a polymeric nanoparticle form of
thyroid hormone agonist, partial agonist or an antagonist to promote or inhibit angiogenesis
in the organism.
Huang et al. [49] demonstrated an implementation of a time-resolved luminescence (TRL)
assay for the sensitive and selective detection of thyroglobulin (Tg), a thyroid cancer marker,
in homogeneous solution using water-soluble alpha-Dmannose-conjugated Au nanodots
(Man-Au NDs). They employed those nanodots as a luminescence sensor for the detection of
the thyroid-cancer marker thyroglobulin (Tg) in homogeneous solutions. Because lumines‐
cence quenching of the Man-Au NDs by Con A is inhibited by Tg selectivity, scientists obtained
a highly sensitive and selective assay for Tg.
Many drugs can be delivered as NP and the opportunities for applying single and combined
experimental medical therapy are almost inexhaustible.
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12. Future works
The other idea is to investigate the effect of ionizing radiation and cancerogens on vascular
structures observed in thyroid tissues. That research might elucidate the pathological changes
similar to those which occur in nuclear atomic disaster survivors and provide knowledge for
the implementation of drugs for radiation damage prevention and cancer treatment.
Could be interesting to develop more works into the endocrine imaging field in order to
improve the differentiation between benign and malignant thyroid lesions.
Regarding the nanotechnology applied to the sphere of endocrine cancers and thyroid disease
in particular, it is difficult to predict all the effects of NP to the alive human organism and that
is why the major sources of experimental evidence are animal studies where tumors are
produced unnaturally and NP are delivered during various stages of pathological process.
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